Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024 Financial statements
Income statement Balance sheet Cash flow
Annual Quarterly
Gross profit4 5 6 7 8 2 $1.9M in 2024-$500.0K 0 $500.0K $1.0M $1.5M $2.0M 2017: $0 $0 2017 2018: -$963 -$963 2018 2019: $14.5K $14.5K 2019 2020: $17.5K $17.5K 2020 +21% 2021: $30.5K $30.5K 2021 +75% 2022: $456.8K $456.8K 2022 +1397% 2023: $1.2M $1.2M 2023 +163% 2024: $1.9M $1.9M 2024 +56% Net income4 5 8 2 -$669.0K in 2024−48% since 2017 -$4.0M -$3.0M -$2.0M -$1.0M 0 2017: -$1.3M -$1.3M 2017 2018: -$3.5M -$3.5M 2018 +167% 2019: -$1.9M -$1.9M 2019 −45% 2020: -$1.2M -$1.2M 2020 −39% 2021: -$1.7M -$1.7M 2021 +46% 2022: -$818.2K -$818.2K 2022 −52% 2023: -$701.2K -$701.2K 2023 −14% 2024: -$669.0K -$669.0K 2024 −5% No quarterly figures reported.
Fiscal year 2017 2018 2019 2020 2021 2022 2023 2024 Gross profit 0 CAD4 -963 CAD5 14.5K CAD6 17.5K CAD7 30.5K CAD8 456.8K CAD2 1.2M CAD2 1.9M CAD2 Net income -1.3M CAD4 -3.5M CAD5 -1.9M CAD5 -1.2M CAD5 -1.7M CAD8 -818.2K CAD2 -701.2K CAD2 -669.0K CAD2 Earnings per share -0 CAD/shares6 -0 CAD/shares7 -0 CAD/shares8 -0 CAD/shares2 -0 CAD/shares2 -0 CAD/shares2 Earnings per share (diluted) -0 CAD/shares8 -0 CAD/shares2 -0 CAD/shares2 -0 CAD/shares2
Total assets9 4 5 6 7 8 2 $2.3M in 2024−21% since 2017 0 $1.0M $2.0M $3.0M 2017: $2.9M $2.9M 2017 2018: $1.2M $1.2M 2018 −59% 2019: $208.4K $208.4K 2019 −83% 2020: $440.1K $440.1K 2020 +111% 2021: $2.3M $2.3M 2021 +418% 2022: $2.6M $2.6M 2022 +13% 2023: $2.5M $2.5M 2023 −1% 2024: $2.3M $2.3M 2024 −9% Total liabilities9 4 5 6 7 8 2 $330.8K in 2024−18% since 2017 0 $500.0K $1.0M $1.5M 2017: $402.1K $402.1K 2017 2018: $314.2K $314.2K 2018 −22% 2019: $673.9K $673.9K 2019 +114% 2020: $1.2M $1.2M 2020 +71% 2021: $84.5K $84.5K 2021 −93% 2022: $604.9K $604.9K 2022 +616% 2023: $529.2K $529.2K 2023 −13% 2024: $330.8K $330.8K 2024 −37% Shareholders’ equity5 6 7 8 2 $2.0M in 2024−21% since 2017 -$1.0M 0 $1.0M $2.0M $3.0M 2017: $2.5M $2.5M 2017 2018: $886.0K $886.0K 2018 −65% 2019: -$465.5K -$465.5K 2019 2020: -$724.0K -$724.0K 2020 +56% 2021: $2.2M $2.2M 2021 2022: $2.0M $2.0M 2022 −11% 2023: $2.0M $2.0M 2023 +2% 2024: $2.0M $2.0M 2024 −2% Cash5 6 7 8 2 $1.1M in 2024+102% since 2017 0 $1.0M $2.0M $3.0M 2017: $559.7K $559.7K 2017 2018: $84.4K $84.4K 2018 −85% 2019: $13.8K $13.8K 2019 −84% 2020: $302.7K $302.7K 2020 +2094% 2021: $2.0M $2.0M 2021 +565% 2022: $620.5K $620.5K 2022 −69% 2023: $276.6K $276.6K 2023 −55% 2024: $1.1M $1.1M 2024 +309% No quarterly figures reported.
Fiscal year 2017 2018 2019 2020 2021 2022 2023 2024 Cash 559.7K CAD5 84.4K CAD6 13.8K CAD7 302.7K CAD8 2.0M CAD2 620.5K CAD2 276.6K CAD2 1.1M CAD2 Total assets 2.9M CAD9 1.2M CAD4 208.4K CAD5 440.1K CAD6 2.3M CAD7 2.6M CAD8 2.5M CAD2 2.3M CAD2 Total liabilities 402.1K CAD9 314.2K CAD4 673.9K CAD5 1.2M CAD6 84.5K CAD7 604.9K CAD8 529.2K CAD2 330.8K CAD2 Shareholders’ equity 2.5M CAD5 886.0K CAD6 -465.5K CAD7 -724.0K CAD8 2.2M CAD2 2.0M CAD2 2.0M CAD2 2.0M CAD2 Shares outstanding 27.9M shares10 0 shares9 0 shares4 0 shares5 97.5M shares6 99.2M shares7 99.6M shares8 101.3M shares2
Cash from operations4 5 6 7 8 2 $1.0M in 2024-$2.0M -$1.0M 0 $1.0M $2.0M 2017: -$1.0M -$1.0M 2017 2018: -$1.4M -$1.4M 2018 +36% 2019: -$686.4K -$686.4K 2019 −51% 2020: -$1.2M -$1.2M 2020 +78% 2021: -$1.2M -$1.2M 2021 +1% 2022: -$437.8K -$437.8K 2022 −65% 2023: $660.4K $660.4K 2023 2024: $1.0M $1.0M 2024 +52% Capital spending9 8 2 $181.1K in 2024+4686% since 2017 0 $500.0K $1.0M $1.5M 2017: $3.8K $3.8K 2017 2018: $5.0K $5.0K 2018 +32% 2021: $105.4K $105.4K 2021 +2007% 2022: $1.2M $1.2M 2022 +1033% 2023: $1.0M $1.0M 2023 −14% 2024: $181.1K $181.1K 2024 −82% Free cash flow4 5 8 2 $823.5K in 2024-$2.0M -$1.0M 0 $1.0M 2017: -$1.0M -$1.0M 2017 2018: -$1.4M -$1.4M 2018 +36% 2021: -$1.3M -$1.3M 2021 −5% 2022: -$1.6M -$1.6M 2022 +22% 2023: -$361.2K -$361.2K 2023 −78% 2024: $823.5K $823.5K 2024 Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Fiscal year 2017 2018 2019 2020 2021 2022 2023 2024 Cash from operations -1.0M CAD4 -1.4M CAD5 -686.4K CAD6 -1.2M CAD7 -1.2M CAD8 -437.8K CAD2 660.4K CAD2 1.0M CAD2 Capital spending 3.8K CAD9 5.0K CAD9 105.4K CAD8 1.2M CAD2 1.0M CAD2 181.1K CAD2 Free cash flow -1.0M CAD -1.4M CAD -1.3M CAD -1.6M CAD -361.2K CAD 823.5K CAD
Compare Avricore Health Inc. with another company
Former names
Vanc Pharmaceuticals Inc. Sep 12, 2014 to Oct 5, 20183 NUVA Pharmaceuticals Inc. Jan 16, 2014 to Jun 17, 20143 ALDA Pharmaceuticals Corp. Mar 20, 2006 to Oct 29, 20133
Recent filings
Oct 13, 2026 6-K Sep 17, 2026 6-K Jul 13, 2026 6-K Jun 11, 2026 6-K May 11, 2026 6-K Feb 17, 2026 6-K Jan 12, 2026 6-K Dec 10, 2025 6-K Sep 15, 2025 6-K Aug 8, 2025 6-K Jul 11, 2025 6-K Jun 16, 2025 20-F Jun 5, 2025 6-K May 20, 2025 6-K Feb 6, 2025 6-K Every filing from the last three years, summarized . The full record is on SEC EDGAR.1
